Health Care · Cell & Gene Therapy
crisprtx revenue, results and funding
crisprtx filed revenue of $3.5M for 2025.
Data updated Nov 19, 2026 · Back to the company report
$3.5MRevenue, 2025
−$581.6MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $3.5M | −$581.6M | $2.3B | $3M | $3.6M | – | $914k | $72.5M | $284.8M | −$664.6M | $347.6M |
| 2024 | $37.3M | −$366.3M | $2.2B | – | $3.6M | – | $1.9M | $86.6M | $310.2M | −$466.6M | $298.3M |
| 2023 | $371.2M | −$153.6M | $2.2B | – | $2.9M | – | $9.5M | $81M | $387.3M | −$222.5M | $389.5M |
| 2022 | $1.2M | −$650.2M | $2.2B | – | −$325k | – | $37.2M | $97.9M | $461.6M | −$673.2M | $211.9M |
| 2021 | $915M | $377.7M | $2.8B | – | $1.9M | – | $81.7M | $102.4M | $340.6M | $373.5M | $923M |
| 2020 | $719k | −$348.9M | $1.8B | – | $809k | – | $18.4M | $66M | $221.4M | −$354.4M | $1.2B |
| 2019 | $289.6M | $66.9M | $1.1B | – | $448k | – | $6.7M | $44.1M | $179.4M | $46.7M | $943.8M |
| 2018 | $3.1M | −$165M | $489M | – | $553k | $57k | $2.8M | $35M | $113.8M | −$158.9M | $456.6M |
| 2017 | $41M | −$68.4M | $271.3M | – | $1.7M | – | $7.8M | $18.9M | $69.8M | −$64.6M | $239.8M |
| 2016 | $5.2M | −$23.2M | $345M | – | $484k | – | $3M | $10.8M | $42.2M | −$68.1M | $315.5M |
| 2015 | $247k | −$25.5M | $159.4M | – | $7k | – | $1.2M | $3.7M | $12.6M | −$25.7M | $156M |
| 2014 | – | −$7M | – | – | −$63k | – | – | $695k | $1.5M | −$6.6M | $945k |
| 2013 | – | – | – | – | – | – | – | – | – | – | $361k |
Sources: SEC
How to cite
crisprtx, Financials. Alion, Nov 19, 2026. https://alion.io/company/crisprtx/financials
